AI Article Synopsis

  • Dihydropyrimidine dehydrogenase (DPYD) regulates the breakdown of pyrimidines, particularly fluorouracil, a chemotherapy drug.
  • The study sequenced samples from 288 individuals across five ethnic groups and identified 56 genetic variations, including 6 known and 18 new polymorphisms.
  • Notably, allele frequencies were similar among Asian populations but varied between Asians and African/American European populations, indicating potential implications for drug response and personalized medicine.

Article Abstract

Dihydropyrimidine dehydrogenase (DPYD) is an enzyme that regulates the rate-limiting step in pyrimidine metabolism, especially catabolism of fluorouracil, a chemotherapeutic agent for cancer. In order to determine the genetic distribution of DPYD, we directly sequenced 288 subjects from five ethnic groups (96 Koreans, 48 Japanese, 48 Han Chinese, 48 African Americans, and 48 European Americans). As a result, 56 polymorphisms were observed, including 6 core polymorphisms and 18 novel polymorphisms. Allele frequencies were nearly the same across the Asian populations, Korean, Han Chinese and Japanese, whereas several SNPs showed different genetic distributions between Asians and other ethnic populations (African American and European American). Additional in silico analysis was performed to predict the function of novel SNPs. One nonsynonymous SNP (+199381A > G, Asn151Asp) was predicted to change its polarity of amino acid (Asn, neutral to Asp, negative). These findings would be valuable for further research, including pharmacogenetic and drug responses studies.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3744698PMC
http://dx.doi.org/10.3346/jkms.2013.28.8.1129DOI Listing

Publication Analysis

Top Keywords

dihydropyrimidine dehydrogenase
8
ethnic groups
8
han chinese
8
screening dihydropyrimidine
4
dehydrogenase genetic
4
genetic variants
4
variants direct
4
direct sequencing
4
sequencing ethnic
4
groups dihydropyrimidine
4

Similar Publications

DPYD genotype should be extended to rare variants: report on two cases of phenotype / genotype discrepancy.

Cancer Chemother Pharmacol

January 2025

Service de Génomique des Tumeurs et Pharmacologie, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris, Paris, France.

The enzyme dihydropyrimidine dehydrogenase (DPD) is the primary catabolic pathway of fluoropyrimidines including 5 fluorouracil (5FU) and capecitabine. Cases of lethal toxicity have been reported in cancer patients with complete DPD deficiency receiving standard dose of 5FU or capecitabine. DPD is encoded by the pharmacogene DPYD in which more than 200 variants have been identified.

View Article and Find Full Text PDF

Pancreatic ductal adenocarcinoma (PDAC) is associated with a poor prognosis, and biomarkers to guide treatment decisions in PDAC are generally lacking. Intratumoural expression of dihydropyrimidine dehydrogenase (DPD) is a potential prognostic parameter in patients with PDAC undergoing surgical resection and postoperative chemotherapy. In the present study, DPD was analysed by immunohistochemistry of a tissue microarray platform including a real-world cohort of 495 patients with PDAC who had undergone resection with curative intent at any of three tertiary centres, including Northern, Western and Southeastern regions of Sweden, between 1993 and 2019.

View Article and Find Full Text PDF

Dihydropyrimidine dehydrogenase (DPD, encoded by the gene) is the rate-limiting enzyme for the detoxification of fluoropyrimidines (FLs). Rs4294451 is a regulatory polymorphism that has recently been functionally characterized and associated with increased DPD expression in the liver. The aim of the present study was to test the clinical implications of being a carrier of rs4294451 in a cohort of 645 FL-treated colorectal cancer patients.

View Article and Find Full Text PDF

Objectives: The use of plasma uracil measurements to detect dihydropyrimidine dehydrogenase (DPD) deficiency is one of the methods for preventing toxicities associated with fluoropyrimidines, including 5-Fluorouracil (5-FU). Unfortunately, this measurement is subject to variations, that may lead to unnecessary dosage reductions and therefore to a reduced efficacy of treatment. Recently, new factors such as hepatic and renal impairment have been proposed as also influencing uracil concentration.

View Article and Find Full Text PDF

Influence of DPYD gene polymorphisms on 5-Fluorouracil toxicities in Thai colorectal cancer patients.

Cancer Chemother Pharmacol

December 2024

Division of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, 10400, Thailand.

Article Synopsis
  • DPYD polymorphisms are linked to toxicities from the chemotherapy drug 5-FU, and this study focused on identifying associations between specific DPYD gene variations and blood-related side effects in Thai colorectal cancer patients.
  • Genetic testing revealed distinct frequencies of DPYD variants, with the homozygous variant DPYD*9A significantly correlating with neutropenia and other hematological toxicities during the first cycle of treatment.
  • The findings suggest that the DPYD*5 variant may act as a predictive marker for lower toxicity levels, highlighting the importance of genetic profiling in managing 5-FU treatment risks.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!